BioSpace News Archive

First Wave BioPharma, Inc. today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation at the 2023 Roth Healthcare Opportunities Conference taking place October 12, 2023, in New York.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Shephard (Shep) Mpofu, MD, MRCP, FRCP as Senior Vice President of Development.

PDS Biotechnology Corporation today announced updated interim data based on an August 2nd cut off from the VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).

Compugen Ltd. today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.

Numinus Wellness is proud to introduce its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness.

Veeva Systems (NYSE: VEEV) today announced that LEO Pharma , a global leader in medical dermatology, is using Veeva Vault Safety to optimize its safety operations.

BPGbio, Inc. today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.

Oxford BioDynamics Receives Reimbursement Code for EpiSwitch ® Prostate Screening (PSE) Test.

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx ® -SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy.

ONI is excited to introduce its latest breakthrough in super-resolution imaging solutions: the ONI Discovery Kit for dSTORM imaging in cells, which helps users prepare their own samples for dSTORM super-resolution microscopy with ease.